ZA202302154B - Methods and compositions for genetic modulation of tumor microenvironments - Google Patents

Methods and compositions for genetic modulation of tumor microenvironments

Info

Publication number
ZA202302154B
ZA202302154B ZA2023/02154A ZA202302154A ZA202302154B ZA 202302154 B ZA202302154 B ZA 202302154B ZA 2023/02154 A ZA2023/02154 A ZA 2023/02154A ZA 202302154 A ZA202302154 A ZA 202302154A ZA 202302154 B ZA202302154 B ZA 202302154B
Authority
ZA
South Africa
Prior art keywords
compositions
methods
tumor microenvironments
genetic modulation
inhibitor
Prior art date
Application number
ZA2023/02154A
Other languages
English (en)
Inventor
Reid P Bissonnette
Rosemary M Cesario
Robert Goodenow
Farbod Shojaei
Mireille Gillings
Original Assignee
Huyabio Int Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huyabio Int Llc filed Critical Huyabio Int Llc
Publication of ZA202302154B publication Critical patent/ZA202302154B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA2023/02154A 2020-08-25 2023-02-21 Methods and compositions for genetic modulation of tumor microenvironments ZA202302154B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063070173P 2020-08-25 2020-08-25
PCT/US2021/047380 WO2022046792A2 (en) 2020-08-25 2021-08-24 Methods and compositions for genetic modulation of tumor microenvironments

Publications (1)

Publication Number Publication Date
ZA202302154B true ZA202302154B (en) 2023-10-25

Family

ID=80355668

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2023/02154A ZA202302154B (en) 2020-08-25 2023-02-21 Methods and compositions for genetic modulation of tumor microenvironments

Country Status (10)

Country Link
US (1) US20220110924A1 (cg-RX-API-DMAC7.html)
EP (1) EP4203955A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023539246A (cg-RX-API-DMAC7.html)
KR (1) KR20230057426A (cg-RX-API-DMAC7.html)
AU (1) AU2021333655A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023003466A2 (cg-RX-API-DMAC7.html)
CA (1) CA3190514A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023002286A (cg-RX-API-DMAC7.html)
WO (1) WO2022046792A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202302154B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4654979A1 (en) * 2023-01-25 2025-12-03 Huyabio International, LLC Methods and compositions comprising a cardio-tolerated hdac inhibitor
CN117357530A (zh) * 2023-11-07 2024-01-09 苏州大学附属儿童医院 Pde3a抑制剂在制备治疗急性髓系白血病的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244751B2 (en) * 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
TWI794171B (zh) * 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) * 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TR201900059A2 (tr) * 2018-01-05 2019-07-22 Gnt Biotech & Medicals Corp Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem

Also Published As

Publication number Publication date
EP4203955A2 (en) 2023-07-05
CA3190514A1 (en) 2022-03-03
KR20230057426A (ko) 2023-04-28
AU2021333655A9 (en) 2024-06-06
JP2023539246A (ja) 2023-09-13
AU2021333655A1 (en) 2023-05-04
EP4203955A4 (en) 2024-09-18
US20220110924A1 (en) 2022-04-14
WO2022046792A3 (en) 2022-04-07
MX2023002286A (es) 2023-05-16
BR112023003466A2 (pt) 2023-05-09
WO2022046792A2 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
MX2025000627A (es) Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos
GEAP202616866A (en) 2-azabicyclo[2.2.1]heptane kras inhibitors
MX2025003821A (es) Compuestos con actividad contra tumores mutantes de kras
MX2025013504A (es) Inhibidores de kras de anillo fundido para el tratamiento de enfermedades
MX2024010999A (es) Compuestos de piperidina 3-sustituidos para inhibicion del protooncogen-b de linfoma de linea b de casitas (cbl-b) y uso de un inhibidor de cbl-b en combinacion con una vacuna contra el cancer y/o con un virus oncolitico.
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
EP4234030A3 (en) Pd-1/pd-l1 inhibitors
CR20230057A (es) Compuestos tríciclicos de urea como inhibidores de jak2 v617f
AU2017266951A1 (en) Use of Glutamate modulating agents with Immunotherapies to treat cancer
MX2022008305A (es) Dosificacion de inhibidores de shp2 y metodos de tratamiento del cancer.
AU2001248701A1 (en) Inhibitors of histone deacetylase
MXPA04002397A (es) Inhibidores de histona deacetilasa.
MXPA05008246A (es) Inhibidores de histona desacetilasa.
PH12021553132A1 (en) Methods of using rad51 inhibitors for treatment of pancreatic cancer
MX2023002286A (es) Metodos y composiciones para modulacion genetica de microambientes tumorales.
MX2024011378A (es) Compuestos de urea triciclica como inhibidores de la variante v617f de la cinasa de janus 2 (jak2).
WO2024006292A3 (en) Methods of treating cancer
WO2024163641A3 (en) Formulations for treating cancer
CR20230408A (es) Compuestos moduladores de gcn2 y usos de los mismos
MX2025003571A (es) Inhibidores de tead y metodos de uso de los mismos
WO2021041539A3 (en) Pyrido-indole analogues as gpx4 inhibitors
MX2024000406A (es) Combinacion de inhibidores de puntos de control y un virus oncolitico para el tratamiento del cancer.
MX2024014121A (es) Metodos y composiciones para el tratamiento del exceso de glucocorticoides
WO2023102162A8 (en) Novel hdac inhibitors and therapeutic use thereof
WO2023055885A3 (en) Ezh2 inhibition in pancreatic cancer